$GLCP
GLOBAL LEADERS CORP

2025 Q1 Form 10-K Financial Statement

#000149315225003478 Filed on January 24, 2025

View on sec.gov

Income Statement

Concept 2025 Q1 2024 Q4 2024
Revenue
YoY Change
Cost Of Revenue $16.71K
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$62.11K
YoY Change -87.59%
Income Tax
% Of Pretax Income
Net Earnings -$62.11K
YoY Change -87.59%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 154.4M shares 154.4M shares
Diluted Shares Outstanding 154.4M shares

Balance Sheet

Concept 2025 Q1 2024 Q4 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $570.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.540K
YoY Change -46.85%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.540K
Total Long-Term Assets $0.00
Total Assets $3.540K
YoY Change -46.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $94.56K
YoY Change 165.88%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $94.56K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$1.534M
YoY Change 4.22%
Common Stock $15.44K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$91.02K
YoY Change
Total Liabilities & Shareholders Equity $3.540K
YoY Change -46.85%

Cashflow Statement

Concept 2025 Q1 2024 Q4 2024
OPERATING ACTIVITIES
Net Income -$62.11K
YoY Change -87.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$70.30K
YoY Change -86.03%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $68.99K
YoY Change -86.32%
NET CHANGE
Cash From Operating Activities -$70.30K
Cash From Investing Activities
Cash From Financing Activities $68.99K
Net Change In Cash -$1.304K
YoY Change -221.08%
FREE CASH FLOW
Cash From Operating Activities -$70.30K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Amendment Flag
AmendmentFlag
false
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
999077
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0001830696
CY2024Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
usd
CY2024Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
usd
CY2024 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2024 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
usd
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-10-31
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--10-31
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity File Number
EntityFileNumber
000-56557
CY2024 dei Entity Registrant Name
EntityRegistrantName
GLOBAL LEADERS CORP.
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0386288
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
Units 2613-18
CY2024 dei Local Phone Number
LocalPhoneNumber
8102 3633
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
true
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2024Q2 dei Entity Public Float
EntityPublicFloat
0 usd
CY2025Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
154394750 shares
CY2024 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2024 GLCP No Insider Trading Flag
NoInsiderTradingFlag
true
CY2024 dei Auditor Firm
AuditorFirmId
572
CY2024 dei Auditor Name
AuditorName
Weinberg & Company, P.A.
CY2024 dei Auditor Location
AuditorLocation
Los Angeles, California
CY2024Q4 us-gaap Cash
Cash
570 usd
CY2023Q4 us-gaap Cash
Cash
1874 usd
CY2024Q4 us-gaap Assets Current
AssetsCurrent
3540 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
6660 usd
CY2024Q4 us-gaap Assets
Assets
3540 usd
CY2023Q4 us-gaap Assets
Assets
6660 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10000 usd
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
94556 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35563 usd
CY2024Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000 shares
CY2024Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154394750 shares
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154394750 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154394750 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154394750 shares
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
15439 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
15439 usd
CY2024Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1424320 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1424320 usd
CY2024Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3332 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3332 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1534107 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1471994 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-91016 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-28903 usd
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3540 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6660 usd
CY2024 us-gaap Cost Of Revenue
CostOfRevenue
16706 usd
CY2024 us-gaap Costs And Expenses
CostsAndExpenses
101243 usd
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
514505 usd
CY2024 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62113 usd
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-500444 usd
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154394750 shares
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154394750 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154365315 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154365315 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-63459 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
535000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-500444 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-28903 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-28903 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-62113 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-91016 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-91016 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-62113 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-500444 usd
CY2024 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-10000 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70297 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-503189 usd
CY2024 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
164872 usd
CY2023 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
19234 usd
CY2024 GLCP Repayment Of Advances From Officerprincipal Shareholder
RepaymentOfAdvancesFromOfficerprincipalShareholder
95879 usd
CY2023 GLCP Repayment Of Advances From Officerprincipal Shareholder
RepaymentOfAdvancesFromOfficerprincipalShareholder
49968 usd
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
535000 usd
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
68993 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
504266 usd
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1304 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1077 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1874 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
797 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
570 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1874 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-62113 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70297 usd
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zzEthnofC0H9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting year. Actual results could differ from those estimates. Significant estimates include estimates for the accrual of potential liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q4 us-gaap Cash
Cash
570 usd
CY2023Q4 us-gaap Cash
Cash
1874 usd
CY2024 us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2023 us-gaap Advertising Expense
AdvertisingExpense
16078 usd
CY2024 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zvMjvXQ2R0Tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended October 31, 2024, two customers accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20241031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zWhAunhJehS4">32</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% (<span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20241031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_z04tgrwVIWw2">16</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% each) of the Company’s revenue. </span>For the year ended October 31, 2023, five customers accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FiveCustomersMember_zs9ILMaS6FSl">100</span>% (one customer for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zcg1QM0Oq7c8">28</span>%, and four customers for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FiveCustomerMember_zW5hpC1OzTrc">18</span>% each) of the Company’s revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended October 31, 2024, one vendor accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20241031__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostsAndExpensesMember_zROuGvMgMFo9" title="Concentration risk percentage">100</span>% of the Company’s cost of service revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended October 31, 2024, and 2023, three vendors accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20241031__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--OperatingExpenseMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeVendorsMember_zBBiljPXfB45" title="Concentration risk percentage">86</span>% (<span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20241031__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--OperatingExpenseMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorOneMember_zIpu1IVZDEw2" title="Concentration risk percentage">39</span>%, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20241031__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--OperatingExpenseMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorTwoMember_zp1Ost3rcZe2" title="Concentration risk percentage">35</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231101__20241031__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--OperatingExpenseMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorThreeMember_zdgHyhVyegJ2" title="Concentration risk percentage">12</span>%) and two vendors accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221101__20231031__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--OperatingExpenseMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--TwoVendorsMember_zrwYAPyRDdW8" title="Concentration risk percentage">75</span>% (<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221101__20231031__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--OperatingExpenseMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorOneMember_zdumoHig4D97" title="Concentration risk percentage">65</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221101__20231031__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--OperatingExpenseMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorTwoMember_zWnyyMd1P887" title="Concentration risk percentage">10</span>%) of the Company’s operating expenses, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62113 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-500444 usd
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2024 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-13044 usd
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-105093 usd
CY2024 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13044 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
105093 usd
CY2024Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
267703 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
254659 usd
CY2024Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
267703 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
254659 usd
CY2024Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
267703 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
254659 usd
CY2024Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0 usd
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0 usd
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
usd
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Entity Address Address Line2
EntityAddressAddressLine2
26/F., Shui On Centre
CY2024 dei Entity Address Address Line3
EntityAddressAddressLine3
6-8 Harbour Road
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
Wanchai
CY2024 dei Entity Address Country
EntityAddressCountry
HK
CY2024 dei City Area Code
CityAreaCode
(852)

Files In Submission

Name View Source Status
0001493152-25-003478-index-headers.html Edgar Link pending
0001493152-25-003478-index.html Edgar Link pending
0001493152-25-003478.txt Edgar Link pending
0001493152-25-003478-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
glcp-20241031.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
glcp-20241031_cal.xml Edgar Link unprocessable
glcp-20241031_def.xml Edgar Link unprocessable
glcp-20241031_lab.xml Edgar Link unprocessable
glcp-20241031_pre.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable